Berlin Heals Holding AG Secures Over 7 Million CHF for Innovative Heart Therapy Research
In a promising development for heart health, Berlin Heals Holding AG, a Swiss MedTech startup, has successfully secured over 7 million CHF in funding. This capital will assist the company in initiating its first studies related to less invasive therapeutic methods for heart failure, a condition that afflicts millions globally.
The company has developed an innovative product known as C-MIC (Cardiac Microcurrent), designed specifically for the treatment of heart failure. Preliminary testing has proven to be successful, and the device is currently undergoing further trials to achieve CE certification. At a recent conference in Boston, Berlin Heals showcased long-term results from initial human studies, which demonstrated promising outcomes for patients with dilated cardiomyopathy.
With the funding raised, Berlin Heals is set to embark on First-In-Human studies aimed at evaluating the effectiveness and safety of their groundbreaking technologies. "This funding will provide an opportunity to innovate several less invasive techniques, each of which will be assessed to identify the method that proves most effective for our pivotal trials, paving the way for FDA and global market entry," stated John Brumfield, CEO of Berlin Heals Holding AG.
The company has shown a commitment to advancing heart failure treatment options. Its approach leverages a constant electrical microcurrent that fosters significant health improvements among affected individuals. The funding will not only support the necessary clinical trials but also bolster development efforts for the first-generation C-MIC device, positioning it for CE submission and future commercial endeavors.
Dr. Felix Baader, the Chairman of the Board, highlighted the impact of the C-MIC device during a recent meeting with patients involved in the studies. He noted the profound difference the technology made in their quality of life, underscoring the company's mission: to restore health and vitality to those suffering from heart failure. With support from both existing and new investors, Berlin Heals is motivated to make strides in its research and product development.
Founded in 2014, Berlin Heals Holding AG has quickly made a name for itself by pioneering novel treatments for heart conditions. With state-of-the-art technology backed by strong clinical evidence, the company is poised to impact the heart health landscape significantly. As they look ahead, the results from their Randomized Clinical Trial are expected to be shared publicly later this year, promising to further validate their innovative approaches to heart failure therapy.
Thus, the company stands at the forefront of cardiac therapy development, with a clear vision to bring effective treatments to market, offering new hope for patients dealing with heart failure. As they prepare for their next steps, the healthcare community watches with keen interest, anticipating the potential breakthroughs their research might yield.
The company has developed an innovative product known as C-MIC (Cardiac Microcurrent), designed specifically for the treatment of heart failure. Preliminary testing has proven to be successful, and the device is currently undergoing further trials to achieve CE certification. At a recent conference in Boston, Berlin Heals showcased long-term results from initial human studies, which demonstrated promising outcomes for patients with dilated cardiomyopathy.
With the funding raised, Berlin Heals is set to embark on First-In-Human studies aimed at evaluating the effectiveness and safety of their groundbreaking technologies. "This funding will provide an opportunity to innovate several less invasive techniques, each of which will be assessed to identify the method that proves most effective for our pivotal trials, paving the way for FDA and global market entry," stated John Brumfield, CEO of Berlin Heals Holding AG.
The company has shown a commitment to advancing heart failure treatment options. Its approach leverages a constant electrical microcurrent that fosters significant health improvements among affected individuals. The funding will not only support the necessary clinical trials but also bolster development efforts for the first-generation C-MIC device, positioning it for CE submission and future commercial endeavors.
Dr. Felix Baader, the Chairman of the Board, highlighted the impact of the C-MIC device during a recent meeting with patients involved in the studies. He noted the profound difference the technology made in their quality of life, underscoring the company's mission: to restore health and vitality to those suffering from heart failure. With support from both existing and new investors, Berlin Heals is motivated to make strides in its research and product development.
Founded in 2014, Berlin Heals Holding AG has quickly made a name for itself by pioneering novel treatments for heart conditions. With state-of-the-art technology backed by strong clinical evidence, the company is poised to impact the heart health landscape significantly. As they look ahead, the results from their Randomized Clinical Trial are expected to be shared publicly later this year, promising to further validate their innovative approaches to heart failure therapy.
Thus, the company stands at the forefront of cardiac therapy development, with a clear vision to bring effective treatments to market, offering new hope for patients dealing with heart failure. As they prepare for their next steps, the healthcare community watches with keen interest, anticipating the potential breakthroughs their research might yield.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.